Current disease status-First occurrence of the leukemia Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the leukemia Posts on Medivizor

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years....

Read More

Comparing intensive and less-intensive treatment for older patients with acute myeloid leukemia

Comparing intensive and less-intensive treatment for older patients with acute myeloid leukemia

Posted by on May 9, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare the safety and effectiveness of intensive and less-intensive therapy for older adults with acute myeloid leukemia (AML).  This study concluded that intensive therapy may lead to better outcomes for these patients when compared to less-intensive therapy.  Some background Older patients with...

Read More

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2  x 4 doses) with or without blinatumomab (Blincyto) in patients with...

Read More

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Posted by on Feb 26, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term survival outcomes of treosulfan (Trecondi)-based versus busulfan (Myleran)-based conditioning treatment in patients with acute myeloid leukemia. This study concluded that treosulfan-based conditioning treatment may have better outcomes for these patients.   Some background...

Read More

Evaluating the gimema LAL-1308 treatment protocol for adolescent and young adult patients with acute lymphoblastic leukemia

Evaluating the gimema LAL-1308 treatment protocol for adolescent and young adult patients with acute lymphoblastic leukemia

Posted by on Jan 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the GIMEMA LAL-1308 treatment protocol in young patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.   This study concluded that this treatment protocol was safe and effective for these patients.  Some background Adolescents and young adults...

Read More

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study...

Read More

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Posted by on Oct 11, 2020 in Leukemia | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...

Read More

The effects of ofatumumab in combination with chemotherapy in patients with (Ph)-negative B-cell acute lymphoblastic leukemia

The effects of ofatumumab in combination with chemotherapy in patients with (Ph)-negative B-cell acute lymphoblastic leukemia

Posted by on Sep 11, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated outcomes of combining ofatumumab (Arzerra) with hyper-CVAD chemotherapy in patients with Philadelphia chromosome (Ph)-negative CD20-positive B-cell acute lymphoblastic leukemia (B-ALL). The authors found that the combination was safe and effective in such patients. Some background Philadelphia chromosome (Ph) is a...

Read More